Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

WEIGHT-LOSS drugs can be a silver bullet for some trying to shed the pounds after years of failure with fad diets and exercise routines. But dodgy vendors selling potentially deadly fake jabs ...

This FTSE 100 stock could be on the verge of stealing enormous chunks of market share from some of the largest pharmaceutical ...